-
公开(公告)号：EP3095484A1
公开(公告)日：2016-11-23
申请号：EP16174260.6
申请日：2012-11-02
申请人： KeyBioscience AG
CPC分类号： C07K14/585 , A61K31/155 , A61K31/64 , A61K38/23 , A61K38/26 , A61K38/28 , A61K2300/00
摘要： Use of a peptide having SEQ ID NO: 18 for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.
摘要翻译： 使用具有SEQ ID NO：18的肽用于治疗I型糖尿病，II型糖尿病，代谢综合征或肥胖症或抑制性红斑狼疮，或用于缓解胰岛素抵抗或用于降低不希望的高空腹血清葡萄糖水平， 或用于降低不希望的高峰血清葡萄糖水平，或用于降低不希望的高峰血清胰岛素水平，或降低对葡萄糖耐量测试的不希望的大响应。
-
公开(公告)号：EP2773365A1
公开(公告)日：2014-09-10
申请号：EP12846423.7
申请日：2012-11-02
申请人： KeyBioscience AG
CPC分类号： C07K14/585 , A61K31/155 , A61K31/64 , A61K38/23 , A61K38/26 , A61K38/28 , A61K2300/00
摘要： Use of a peptide having SEQ ID NO: 18 for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.
-
公开(公告)号：EP2389388B1
公开(公告)日：2017-03-08
申请号：EP10733943.4
申请日：2010-01-22
申请人： KeyBioscience AG
CPC分类号： A61K38/1706 , A61K9/0053 , A61K9/28 , A61K9/4891 , A61K38/00 , C07K14/00 , C07K14/585
摘要： The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.
-
公开(公告)号：EP2773365B1
公开(公告)日：2016-07-20
申请号：EP12846423.7
申请日：2012-11-02
申请人： KeyBioscience AG
CPC分类号： C07K14/585 , A61K31/155 , A61K31/64 , A61K38/23 , A61K38/26 , A61K38/28 , A61K2300/00
摘要： Use of a peptide having SEQ ID NO: 18 for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.
-
公开(公告)号：EP3357540A1
公开(公告)日：2018-08-08
申请号：EP18161594.9
申请日：2012-11-02
申请人： KeyBioscience AG
CPC分类号： C07K14/585 , A61K31/155 , A61K31/64 , A61K38/23 , A61K38/26 , A61K38/28 , A61K2300/00
摘要： A pharmaceutical co-formulation comprising a calcitonin mimetic and an insulin sensitiser, and its use in the treatment type I diabetes, type II diabetes or a metabolic syndrome, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.
-
公开(公告)号：EP3095484B1
公开(公告)日：2018-05-02
申请号：EP16174260.6
申请日：2012-11-02
申请人： KeyBioscience AG
CPC分类号： C07K14/585 , A61K31/155 , A61K31/64 , A61K38/23 , A61K38/26 , A61K38/28 , A61K2300/00
摘要： Use of a peptide having SEQ ID NO: 18 for the treatment of type I diabetes, Type II diabetes, metabolic syndrome, or obesity, or of apetite suppression, or for mitigating insulin resistance, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.01 秒)
